Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Combining Keytruda, Imprime PGG Nearly Doubles Survival Rate for TNBC Patients Compared to Keytruda Alone

Combining Keytruda, Imprime PGG Nearly Doubles Survival Rate for TNBC Patients Compared to Keytruda Alone

Apr 30, 2020
|
Christie Rizk

NEW YORK – The combination of anti-PD-1 immunotherapy pembrolizumab (Merck's Keytruda) with Imprime PGG, a dectin receptor agonist being developed by Biothera Pharmaceuticals, nearly doubled the median overall survival rate for metastatic triple-negative breast cancer (mTNBC) patients in a Phase II clinical trial of the combination compared to pembrolizumab monotherapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Featured Webinar

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

What's Popular?

In Cancer

  1. Genentech, OneOncology Partner on Genomic Profiling for Personalized Cancer Care

  2. SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach

    Premium

  3. FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

  4. Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program

  5. Persephone Biosciences Launches Study to Assess Microbiome's Role in Cancer Treatment Response

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.